BMRA Biomerica Inc.

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.

About Biomerica (NASDAQ: )

Biomerica, Inc. (www..com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica is primarily focused on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

Corporate Contact:

Zack Irani

949-645-2111

Source: Biomerica, Inc.



EN
10/11/2023

Underlying

BMRABiomerica Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biomerica Inc.

 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved...

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy Physician Interview Now Available Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New intervie...

February 26, 2026 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution

Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution Approval Marks Biomerica’s Strategic Entry into Southeast Asia’s Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam’s Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is workin...

February 18, 2026 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

Biomerica Reports Second Quarter Fiscal 2026 Financial Results Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights:  1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein     During the second quarter, Biomerica ente...

January 14, 2026 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionar...

Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after January 1, 2026.Adults of Medicare age comprise over 20% of US adults and a substantial portion of patients with IBS symptoms, making Medicare a critical payer for inFoods® IBS. IRVINE, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMR...

December 23, 2025 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test...

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch